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Abstract Four different human tissues and breast cancer cell
lines were screened to identify exon deletion variant transcripts
of estrogen receptor L (ERL) by reverse transcription-polymerase
chain reaction using the ‘splice targeted primer approach’ that
amplifies each category of exon deleted variants as a separate
gene population. A total of 10 different variant mRNAs that have
deletions in various combination of exons were identified by
sequence analysis. They were exon 2v; exons 2 and 5^6v; exon
3v; exon 4v; exon 5v; exons 5 and 2v; exon 6v; exons 6 and
2v; exons 6, 2^3v; and exons 5^6v. In some cases, deletion of an
exon appears to be associated with a mutation of a specific base.
Although ERK and ERL are highly homologous, have identical
exon and functional domain organization, exhibit similar ligand-
binding profiles and interact with identical DNA response
elements, the sequence of exon skipping in ERL pre-mRNA
appears to be distinct from that of ERK mRNA. Furthermore,
results described here also suggest that alternate splicing of ERL
mRNA is tissue specific. The presence of a ERL variant profile
together with other ER isoforms in a tissue may have func-
tional implications in binding and response to a particular
ligand. ß 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The steroid hormone, estrogen, is a key regulator of
growth, di¡erentiation and function of a number of tissues
including the male and female reproductive tracts, gastroin-
testinal tract, mammary gland, cardiovascular, skeletal, ner-
vous and immune systems. The biological e¡ects of estrogens
are mediated through four di¡erent estrogen receptor (ER)
pathways: (1) classical ligand-dependent [1], (2) ligand-inde-
pendent [2], (3) DNA-binding-independent [3] and (4) cell sur-
face non-genomic signaling [4]. It is now well established that
the ¢rst three pathways are mediated through two structurally
related but distinct receptors, the ERK and ERL, which have
functional domain characteristics of the superfamily of nu-
clear receptors. The ERK and ERL are highly homologous
in DNA- and ligand-binding domains (97 and 60%, respec-
tively) [5], exhibit similar binding pro¢les to estrogens and
interact with identical DNA response elements [6]. Expression
patterns of these two receptors suggested that ERK and ERL
genes are di¡erentially expressed in various tissues. The ex-
pression of ERK seems to predominate in the female repro-
ductive organs and ERL predominates in non-reproductive
organs and the male reproductive tract [5,7]. In vitro studies
have shown that ERL has overlapping but distinct transcrip-
tional properties compared to ERK [8]. ERL markedly di¡ers
from ERK in activating genes at AP-1 promoter sites. In ad-
dition to possessing a constitutive transactivating property in
the absence of ligands [9], ERL seems to inhibit the transcrip-
tion of genes at AP-1 sites when bound to agonists [10]. These
di¡erences in the transactivating properties between the two
receptors together with di¡erential expression in di¡erent or-
gans are thought to be the basis for tissue speci¢c agonist/
antagonistic actions of SERMS (selected estrogen receptor
modulators) [11]. However, it is not known whether the ex-
pression of speci¢c structurally altered/truncated functionally
active ER isoforms also correlate with tissue speci¢c actions
of SERMS since most of the estrogen-responsive tissues also
express a number of ERs that have deletions in portions of
the molecules in addition to the two wild-type ERs. Exami-
nation of exon deletion variants of ERK has shown that the
deletions could be either a partial or a complete exon or more
than one exon in sequence or at distant ends of ER molecule.
A total of 20 di¡erent exon deletion variant mRNAs have
been identi¢ed for ERK by reverse transcription-polymerase
chain reaction (RT-PCR) using a novel ‘splice targeted primer
approach’ that detects each category of splice variants as a
separate gene population [12^13]. They were exon 2v ; exons 2
and 7v ; exons 2 and 4v ; exons 2 and 5v ; exons 2, 5 and 7v ;
exons 2, 4^5v ; exons 2, 4^6v ; exon 3v ; exons 3 and 7v ;
exons 2^3v ; exons 2^3 and 7v ; exons 2^3, 5 and 7v ; exon
4v ; exons 4 and 7v ; exon 5v ; exon 6v ; exons 6 and 4v ; exon
7v ; exons 7 and 3^4v ; and exons 7 and 3^5v. Fifteen of the
20 identi¢ed variants were detected both in normal and neo-
plastic tissues of the breast [14]. However, not every identi¢ed
variant was detected in every tissue analyzed suggesting that
the expression of variants is not uniform. Among the 15 var-
iants identi¢ed, the transcripts that have deletions of exon 3
and exon 5 were elevated in cancer tissues compared to nor-
mal tissues. In addition, cancer tissues showed an increased
frequency of multiple exon deletion variants. These two ob-
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servations suggested that ERK mRNA undergoes aberrant
splicing during malignant transformation [14,15].
Although the protein products of all spliced variants have
not been characterized due to practical limitations of their
detection, some of the translated protein products such as
the predicted protein product of ERK exon 5v has been found
naturally in the breast tissues [16]. A few ERL variant proteins
were also described, but their identities were not characterized
[17].
In vitro functional analysis of ERK splice variants have
shown that exon 5v and exon 3v proteins translocate to the
nucleus and are transcriptionally active. In addition, these two
proteins inhibit the wild-type receptor by forming hetero-
dimers and competing for the co-activator, SRC-1e. Exon
5v variant protein exhibits constitutive transactivating prop-
erty in the absence of hormones. Exon 3v variant protein
binds ligands with the same a⁄nity as the wild-type receptor
and has transactivating property at AP-1 sites. Based on these
observations, it was proposed that the splice variants act as
regulators of gene transcription [18].
The ERL splice variants are only beginning to be identi¢ed
and characterized. Three di¡erent ERL variant mRNAs that
have deletions in exon 5 or 6 or exons 5^6 have been identi¢ed
in human breast, uterus and ovary tissues by co-ampli¢cation
with wild-type receptor sequences [19^21]. Due to several lim-
itations as described [12], co-ampli¢cation of alternatively
spliced transcripts along with wild-type receptor sequences
was not found to be an e⁄cient method for identifying all
the splice variant mRNAs. In the current study, we analyzed
normal human ovary, breast, uterus and bone tissues and two
ERK-positive and two ERK-negative breast cancer cell lines
by RT-PCR using the highly sensitive ‘splice targeted primer
approach’ to identify ERL exon deletion variants. Ten di¡er-
ent mRNAs that have deletions in various combinations of
exons were detected. Our results also indicate that although
both ERK and ERL are highly homologous, have similar exon
and domain organizations and exhibit similar binding pro¢les
to estrogens and interact with identical DNA response ele-
ments, they have distinct mRNA alternate splicing patterns.
Furthermore, expression of ERL splice variants appears to be
tissue speci¢c.
2. Materials and methods
HotStartTaq PCR core kits, Omniscript reverse transcriptase and
MinElute gel extraction kits were from Qiagen, Santa Clara, CA,
USA. All the primers used in the current study were synthesized by
Gibco-BRL Life Technologies. The pCR02.1-TOPO cloning vector
was obtained from Invitrogen. PCR quality water and Tris^EDTA
bu¡er were from BioWhittaker. Primary cultures of human osteo-
blasts prepared from trabecular regions of the bone were obtained
from Clonetics, normal human ovary and uterus tissues were obtained
from Howard University Hospital. They were collected from women
undergoing hysterectomy for non-malignant conditions. Total RNA
from normal breast tissues, breast cancer cell lines and tumors were
available from previous studies [13^15,22,23].
2.1. RNA extraction and cDNA synthesis
Total RNA was extracted from frozen human ovary, uterus and
primary osteoblasts using Trizol reagent (Gibco-BRL Life Technolo-
gies) as described previously [15,22,23]. RNA integrity was veri¢ed by
both electrophoresis in 1.5% agarose gels and RT-PCR of the con-
stitutively expressed gene, glyceraldehyde-3 phosphate dehydrogenase
(GAPDH). The isolated RNA was reverse transcribed using Omni-
script reverse transcriptase as previously described [15,23]. Brie£y, the
standard mixture contained 1 Wg of total RNA, 10 U of RNase in-
hibitor, 0.5 mM each of dNTPs, 1.0 WM random hexamers and 4 U of
Omniscript reverse transcriptase in a total volume of 20 Wl. For re-
verse transcription, tubes were incubated at 37‡C for 60 min, followed
by 95‡C for 5 min and ¢nally rapidly cooled.
2.2. PCR
PCRs were performed in an automatic thermal cycler (MJ Re-
search) as previously described [24] in a total volume of 12.5 Wl con-
taining the cDNA, reverse transcribed from 125 ng of total RNA,
1UPCR bu¡er, 1UQ solution, 200 WM each of dNTPs, 2WM each
of sense and anti-sense primers and 0.6 U of HotStartTaq polymerase.
GAPDH was ampli¢ed in parallel for only 25 cycles with cDNA
reverse transcribed from 50 ng of total RNA. The PCR conditions
were initial denaturation for 1 min at 95‡C, followed by 94‡C for
1 min, annealing for 1 min at the speci¢ed temperature depending
on the primer pair used, extension for 2 min at 72‡C for 40 cycles
and ¢nal extension for 15 min at 72‡C. The annealing temperature for
ampli¢cation of all the transcripts described below is 55‡C except for
exons 5^6v transcripts. To amplify these transcripts, annealing tem-
perature was 61‡C. The wild-type ERK sequences were ampli¢ed using
a sense primer, ERKS, 5P-TGCCCTACTACCTGGAGAACG-3P (po-
sition, exon 1, bp 615^635) and an anti-sense primer, ERKA, 5P-
GTCCTTCTCTTCCAGAGAC-3P (position, exon 7, bp 1651^1633).
ERL wild-type sequences were ampli¢ed using a sense primer, ERLS,
5P-CGCTAGAACACACCTTACCTG-3P (position, exon 1, bp 433^
453) and an anti-sense primer, ERL1A, 5P-CTGTGACCAGAGGG-
TACAT-3P (position, exon 7, bp 1344^1326). The ‘splice targeted
primers’ for amplifying ERL exon 2v, exon 3v, exon 4v, exon 5v,
exon 6v, exons 5^6v, and exon 7v transcripts were ERL SX1/3, 5P-
ACCTTACCTGTAAACAG1/3GACA-3P (positions, exon 1, bp 444^
460 and exon 3, bp 634^637), ERLSX2/4, 5P-TAAAAGAAGCATT-
CAAG2/4GCTC-3P (positions, exon 2, bp 617^633 and exon 4, bp
751^754), ERLSX 3/5, 5P-GAATGGTGAAGTGTG3/5GCTTTG-3P
(positions, exon 3, bp 736^750 and exon 5, bp 1051^1056), ERLAX
6/4, 5P-GCATTTCCCCTCATCC6/4CGGGA-3P (positions, exon 6,
bp 1190^1205 and exon 4, bp 1046^1050), ERLAX 7/5, 5P-GACCA-
GAGGGTACATAC7/5CTGT-3P (positions, exon 7, bp 1340^1324
and exon 5, bp 1189^1186), ERLAX 7/4, 5P-CCAGAGGGTACA-
TAC7/4CGGGAA-3P (positions, exon 7, bp 1340^1324 and exon 4,
bp 1045^1050), and ERLAX8/6, 5P-GTTCCATGCCCTTGTTA8/
6TGGA-3P (positions, exon 6, bp 1320^1323 and exon 8, bp 1505^
1521), respectively. The partner primer for 2v, 3v and 4v was ERL2A,
5P-TTGAGCAGATGTTCCATGCCC-3P (position, exon 8, bp 1511^
1531). For 5v, 6v, 5^6v and 7v, the partner primer was ERLS. The
design, speci¢city, and applicability of splice targeted primers in am-
plifying and quantifying alternatively spliced ER mRNAs as separate
gene populations in cell lines and tissues have been well established
[12^15,23]. The GAPDH was ampli¢ed using a sense primer, 5P-AA-
GGCTGAGAACGGGAAGCTTGTCATCAAT-3P (position, exon 3,
bp 241^270) and an anti-sense primer, 5P-TTCCCGTCTAGCT-
CAGGGATGACCTTGCCC-3P (position, exon 7, bp 740^711) [25].
The sequence and locations of ER primers are based on the full-length
cDNA sequences [26^27].
2.3. Detection and identi¢cation of PCR products
The PCR ampli¢ed products (6.5 Wl each) were separated by elec-
trophoresis in 1% agarose gels in Tris^acetic acid^EDTA bu¡er and
detected by ethidium bromide staining. To detect the PCR products of
GAPDH, 1 Wl was used. The identities of the PCR ampli¢ed ER
products were determined by cloning the gel puri¢ed products into
pCR02.1-TOPO vector and sequence analysis as previously described
[13^15].
3. Results and discussion
Alternate splicing of pre-mRNAs is thought to be one of
the cellular mechanisms for generating a functionally diverse
pool of gene products derived from a single gene. It is also
recognized as a process that contributes to the complexity and
diversity of human proteome given the presence of only 30 000
to 40 000 structural genes [28^29], just twice as many as for a
worm or a £y. Alternate splicing is also recognized as an
important mechanism for regulating the wild-type proteins.
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For example, two splice variants of ERK, the exon 3v and 5v
have been shown to modulate the wild-type receptor [18] in
addition to possessing their own functional activities. The
wild-type bullfrog glucocorticoid receptor-3 (bfGnRHR-3) ac-
tivity has also been shown to be inhibited by alternatively
spliced variant proteins in a dose-dependent manner [30]. In
this case, splice variant proteins did not show any transcrip-
tional activity. A recent analysis of human expressed tag data-
bases showed that 38% of human primary transcripts are al-
ternatively spliced and there are approximately 2.75 splice
forms per di¡erentially spliced transcript [31].
Although the presence of alternatively spliced variants for
several genes has been known for some time, little is known
about the factors that regulate this process. In particular it is
not known whether the sequence of exon skipping in a pre-
mRNA is speci¢c to the gene or the type of tissue. In the
current study we have examined the alternate splicing pattern
of ERL mRNA and compared it with the closely related ERK
mRNA. To detect all the possible ERL splice variant tran-
scripts, we analyzed four di¡erent estrogen-responsive human
tissues, breast, ovary, uterus and bone tissues and four di¡er-
ent breast cancer cell lines by RT-PCR using a highly speci¢c
‘splice targeted primer approach’. For comparative purposes,
we also ampli¢ed wild-type ERK and ERL mRNAs.
The expression of ERK and ERL wild-type (exon 1^7), 10
exon deletion variants of ERL in ovary, uterus, bone and
breast tissues, two ERK-positive breast cancer cell lines
(MCF-7 and LCC1) and two ERK-negative breast cancer
cell lines (MDA-MB-435 and MDA-MB-231) are shown in
Figs. 1 and 2, respectively, and in Table 1. Ten exon deletion
variants of ErL were identi¢ed. They were exon 2v, exons 2
and 5^6v, exon 3v, exon 4v, exon 5v, exons 5 and 2v, exon
6v, exons 6 and 2v, exons 6 and 2^3v, and exons 5 and 6v
(Fig. 3). Among all the tissues and cell lines examined only
ovary showed the presence of nine of the 10 identi¢ed tran-
scripts (Fig. 3, Table 1). Although the wild-type receptors
were not detected in bone tissue (osteoblasts) presumably
due to low level of expression, two exon deletion variants
Fig. 1. Expression of ERK and ERL wild-type mRNA in ovary, uterus, breast and bone tissues and breast cancer cell lines. The cDNAs from
the tissues and cell lines were ampli¢ed for ERK and ERL wild-type (exon 1^7) by RT-PCR as described in Section 2. 6 Wl of the PCR ampli-
¢ed products were analyzed by agarose gel electrophoresis and detected by ethidium bromide staining. The house keeping gene, GAPDH gene,
was ampli¢ed in parallel.
Table 1

























MCF-7 + + 3 3 3 + 3 3 3 3 + 3
LCC1 + + + 3 3 + 3 3 + 3 + +
MDA-MB-435 + 3 3 3 3 3 3 3 3 3 + 3
MDA-MB-231 3 + + 3 3 + + 3 3 3 3 3
Ovary + + + + + + + + + 3 + +
Uterus + + 3 3 3 + 3 + 3 + + +
Bone 3 3 3 3 3 3 + 3 3 3 3 +
Breast tumor 1 + 3 + 3 3 3 3 3 3 3 3 3
Normal breast 1 + + 3 3 3 + 3 + 3 3 + +
Normal breast 2 3 + 3 3 3 3 3 + 3 3 + 3
Breast tumor 2 + + 3 3 3 3 3 + 3 3 3 3
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Fig. 2. Expression of ERL exon deletion variants in ovary, uterus, breast and bone tissues and breast cancer cell lines. Exon deletion variant
mRNAs were ampli¢ed by RT-PCR using splice targeted primers. Partner primers were either in exon 1 or 8 depending upon the targeted
primer used. This permitted the ampli¢cation of transcripts with multiple exon deletions in distant exons. PCR ampli¢ed products were identi-
¢ed by cloning and sequence analysis as described in Section 2. Expression of 10 identi¢ed exon deletion variants in various tissues and cell
lines are shown. GAPDH was ampli¢ed in parallel.
Fig. 3. Schematic diagram of 10 human ERL exon deletion variants. The wild-type and 10 exon deletion variant mRNAs identi¢ed are repre-
sented.
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were detected. The ERK-negative cell line, MDA-MB-435,
although it did not show the presence of any ERL wild-
type, was positive for the presence of exons 5^6v transcript.
Interestingly, breast tumor 1 and normal breast tissues 2, each
showed the expression of only one type of ER isoform tran-
scripts. ERL exon 7 deletion variants, which are the most
abundant among the ERK mRNAs (13^14), are not detected
in any of the tissues or cell lines analyzed. The results shown
in Figs. 1 and 2 and Table 1 also suggest that expression of
ERL exon deleted variants is tissue speci¢c.
Sequence analyses of both strands of the above variants
also revealed several base changes in various transcripts as
summarized in Table 2. We observed that deletion of a second
exon in exon 5v transcript is associated with a deletion muta-
tion (position, exon 4, bp 1035). This deletion mutation was
observed in exons 5^6v, exons 5 and 2v and exons 5^6, and
2v transcripts (Table 2). We also observed an association
between exon 6 deletion and substitution of base A in the
place of G (position, exon 3, bp 717). This substitution muta-
tion was observed in exon 6v and exon 6 and 2v transcripts.
The functional signi¢cance of these mutations is not known.
Examination of the sequence of exon deletions in ERL
mRNA suggests that it is distinct from that of ERK
mRNA. Our data on ERK splice variants indicated that
exon 2 was the most commonly deleted exon since it was
detected in every normal breast tissue analyzed, and 10 of
the 20 exon deleted variants had the deletion of exon 2 [13^
14]. Our studies also suggested that initial deletion of an exon
in a transcript is mostly followed by the deletion of exon 7,
and the third most common exon to be deleted after the
deletion of exon 7 is exon 5. After the deletion of exon 2 in
a transcript, if the second deletion is initiated at exon 4, the
deletions seem to proceed up to exon 5 or 6. Initial deletion of
exon 7 in a transcript seem to always follow the deletion of
either exon 3 or exon 4 and proceed up to exon 5. Exon
deletions of ERL mRNA appear to be not as extensive as
ERK since only 10 mRNAs were detected while 20 ERK
were identi¢ed. Deletion of exon 6 which is very rare in
ERK mRNA [13^14] appears to be one of the most frequently
deleted exon of ERL mRNA. Exon 2 appears to be as fre-
quently deleted as exon 6 in an ERL mRNA. Detection of
exons 5 and 2v, exons 6 and 2v, exons 6 and 2^3v and exons
5^6 and 2v mRNAs suggests that deletion of exon 2 is asso-
ciated with the deletion of exon 5 and/or 6. However, it is not
clear whether the deletion of exon 2 in an ERL mRNA pre-
cedes or follows the deletion of exon 5 or 6 or 5^6.
Deletion of exon 2, 5 or 6 in ERL mRNA causes a frame
shift mutation resulting in premature termination of transla-
tion, thereby generating a diverse class of C-terminally trun-
cated receptor forms. Deletion of either exon 3 or 4 does not
disrupt the mRNA reading frame, but produces receptor pro-
teins with internal deletions. The proteins translated from
exon 2v and 4v lack nuclear localization signals and remain
in cytoplasm. The proteins translated from exon 3 deletion
results in an in-frame loss of 117 nucleotides that encode 39
amino acid (aa) in the carboxyl-terminal half of the DNA-
binding domain (DBD), including the second zinc ¢nger. The
exon 5 and 6 deleted splice variant proteins are unlikely to
bind ligands because of truncation in the ligand-binding re-
gion. The exon 5^6 deleted splice variant is in frame but
deleted in 91 aa which are within the hormone-binding do-
mains and has glycine at aa residue 409 instead of serine. A
putative protein encoded by exon 5^6 deleted variant will
have lower a⁄nity for ligands. However, it will retain the
AF-2 site required for binding with co-activators and co-re-
pressors. The multiple exon deleted transcripts, exons 5 and
2v, exons 6 and 2v, exons 6, 2^3v, and exons 2,5^6v are
likely to generate proteins that are defective in either ligand
binding or DNA binding or both.
There has been a debate for a long time whether the ER
splice variant mRNAs are translated into proteins and the
truncated ERs are functionally active. Recent reports show
that both ERK and ERL splice variant mRNAs are translated
into proteins [16^17] and ERK exon 5v and 3v proteins are
functionally active in ligand binding and transactivation [18]
as described earlier. Since portions of the variant molecules
retain the structural characteristics of intact receptor, these
proteins may directly or indirectly participate in ligand bind-
ing and transactivating properties by protein^protein interac-
tions. The ERL exon 3v and 5v proteins, by analogy to ERK
variants, could translocate into the nucleus and may modulate
the wild-type receptor. Exon 6v and exons 5^6v proteins,
although lacking portions of ligand-binding domain, have
the nuclear localization signal and, therefore, may translocate
to the nucleus, bind EREs and modulate the transactivation
property of the wild-type receptor similar to ERK exon 5v
protein. In addition, exons 5^6 deletion variant proteins
may be involved in binding to co-repressors and co-activators
and regulate the wild-type receptor. Proteins translated from
other single and multiple exon deletion variant transcripts that
lack nuclear localization signal may remain in the cytoplasm.
The functional properties of cytosol localized splice variant
ER proteins are not known. It remains to be established
whether the cytosol localized splice variant proteins are in-
volved in cross talk between the growth factor receptor medi-
ated intracellular kinase pathways and ligand independent
transactivation of nuclear ERs.
The results presented in Figs. 1 and 2 also show consider-
able di¡erences in the expression pro¢les of ER isoforms in
various estrogen-responsive tissues. It remains to be estab-
lished whether di¡erential expression of types and relative
levels of various ER isoforms are the basis for tissue speci¢c
agonist/antagonistic actions of SERMS.
Table 2
Summary of base changes in ERL exon deleted transcripts
Variant Base position Base in wild-type Base in variant





Exon 3v 1347 T C
Exon 4v 1078 A ^
Exons 5 and 2v 989 A ^
1035 C ^
Exons 5^6v 1000 A ^
1035 C ^
Exons 5^6, 2v 1035 C ^
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